Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Wei-Li He · SciRah

Researcher profile · Semantic Scholar

Wei-Li He

Share profile

Wei-Li He — researcher profile on SciRah

h-index: 17
Works: 65
Citations: 984

Most-cited papers

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
A. B. Jensen, C. Wynne, G. Ramírez, Wei-Li He +5 more
2010Clinical Breast Cancer142 citations
Semantic Scholar
Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
Janet L. Roberts, Virginia C. Fiedler, Julianne Imperato-McGinley, David A. Whiting +29 more
1999Journal of American Academy of Dermatology131 citations
Semantic Scholar
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
Arthur J. Bergman, G. Murphy, Joanne Burke, Jamie J. Zhao +9 more
2004Journal of clinical pharmacology97 citations
Semantic Scholar
Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases
M. Rosenthal, Peter Davidson, F. Rolland, M. Campone +6 more
2010Asia-Pacific Journal of Clinical Oncology49 citations
Semantic Scholar
The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis
M. Ho, M. V. van der Laan, Hana Lee, Jie Chen +12 more
2021Statistics in Biopharmaceutical Research46 citations
Semantic Scholar
Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment
Mark S. Levenson, Wei-Li He, Jie Chen, Yixin Fang +8 more
2021Statistics in Biopharmaceutical Research41 citations
Semantic Scholar
Functional catalysts for polysulfide conversion in Li–S batteries: from micro/nanoscale to single atom
Wei-Min Zhao, Jian-Gang Shen, Xi-Jun Xu, Wei-Li He +3 more
2022Rare Metals38 citations
Semantic Scholar
Alendronate with and without cholecalciferol for osteoporosis: results of a 15‐week randomized controlled trial*
R. Recker, P. Lips, D. Felsenberg, K. Lippuner +8 more
2006Current Medical Research and Opinion32 citations
Semantic Scholar
The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis
Jie Chen, M. Ho, Kwan Lee, Yang Song +13 more
2021Statistics in Biopharmaceutical Research30 citations
Semantic Scholar
A model‐based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials
Wei-Li He, Jun Liu, B. Binkowitz, H. Quan
2006Statistics in Medicine30 citations
Semantic Scholar
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job
S. Evans, R. Bigelow, C. Chuang-Stein, S. Ellenberg +4 more
2019Annals of Internal Medicine26 citations
Semantic Scholar
Practical Considerations for Adaptive Trial Design and Implementation
Wei-Li He, J. Pinheiro, O. Kuznetsova
201424 citations
Semantic Scholar
Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial
A. B. Jensen, N. Olmeo, C. Wynne, G. Ramírez +6 more
200823 citations
Semantic Scholar
Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine
J. Simon, J. Chandler, K. Gottesdiener, Nicole Lazarus +4 more
2014Menopause19 citations
Semantic Scholar
The Vacuum-Assisted Breast Biopsy System is an Effective Strategy for the Treatment of Gynecomastia
S. Qu, Wei Zhang, Shu-Qin Li, Wei-Li He +4 more
2020Aesthetic Plastic Surgery18 citations
Semantic Scholar
Benefit-Risk Evaluation and Decision Making: Some Practical Insights
M. Colopy, C. Damaraju, Wei-Li He, Qi Jiang +3 more
2015Therapeutic Innovation and Regulatory Science18 citations
Semantic Scholar
Practical Considerations and Strategies for Executing Adaptive Clinical Trials
Wei-Li He, O. Kuznetsova, M. Harmer, C. Leahy +6 more
201218 citations
Semantic Scholar
Key considerations in the design of real-world studies.
Yixin Fang, Wei-Li He, Hongwei Wang, Meijing Wu
2020Contemporary Clinical Trials17 citations
Semantic Scholar
A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence
Yixin Fang, Hongwei Wang, Wei-Li He
2019Therapeutic Innovation and Regulatory Science16 citations
Semantic Scholar
Estimands in Real-World Evidence Studies
Jie Chen, Daniel O. Scharfstein, Hongwei Wang, Bin-Bing Yu +5 more
2023Statistics in Biopharmaceutical Research12 citations Open access
Semantic Scholar
A new framework to address challenges in quantitative benefit-risk assessment for medical products.
Bo Fu, Xuefeng Li, John Scott, Wei-Li He
2020Contemporary Clinical Trials11 citations
Semantic Scholar
DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs
Eva R. Miller, Paul P. Gallo, Wei-Li He, L. Kammerman +8 more
2017Therapeutic Innovation and Regulatory Science11 citations
Semantic Scholar
Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs
Wei-Li He, Paul P. Gallo, Eva R. Miller, Y. Jemiai +6 more
2017Therapeutic Innovation and Regulatory Science10 citations Open access
Semantic Scholar
The Case for a Bayesian Approach to Benefit-Risk Assessment: Overview and Future Directions
M. J. Costa, Wei-Li He, Y. Jemiai, Yue-Qin Zhao +1 more
2017Therapeutic Innovation and Regulatory Science10 citations
Semantic Scholar
A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selection
Wei-Li He, Xi-Ting Cao, Lu-wei Xu
2012Statistics in Medicine10 citations
Semantic Scholar
A method for sample size calculation via E‐value in the planning of observational studies
Yixin Fang, Wei-Li He, Xiaofei Hu, Hongwei Wang
2020Pharmaceutical statistics9 citations
Semantic Scholar
Intraspinal administration of interleukin-7 promotes neuronal apoptosis and limits functional recovery through JAK/STAT5 pathway following spinal cord injury.
Xiao-Chen Yuan, Qing-Bin Wu, Peng Wang, Yingli Jing +7 more
2019Biochemical and Biophysical Research Communications - BBRC9 citations
Semantic Scholar
Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development
M. Levenson, Wei-Li He, Li Chen, S. Dharmarajan +4 more
2022Statistics in Biopharmaceutical Research8 citations
Semantic Scholar
Benefit-Risk Assessment Methods in Medical Product Development : Bridging Qualitative and Quantitative Assessments
Qi Jiang, Wei-Li He
20176 citations
Semantic Scholar
Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product
Haijun Ma, Qi Jiang, C. Chuang-Stein, S. Evans +5 more
20166 citations
Semantic Scholar
Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages
Shihua Wen, Wei-Li He, S. Evans, G. Quartey +5 more
20166 citations
Semantic Scholar
Teasing Out the Overall Survival Benefit With Adjustment for Treatment Switching to Multiple Treatments
Yuqing Xu, Meijing Wu, Wei-Li He, Qi-Ming M. Liao +1 more
2021Statistics in Biopharmaceutical Research5 citations
Semantic Scholar
Benefit–Risk Evaluation Using a Framework of Joint Modeling and Joint Evaluations of Multiple Efficacy and Safety Endpoints
Wei-Li He, Bo Fu
20175 citations
Semantic Scholar
Clinical Trials with External Control: Beyond Propensity Score Matching
Hongwei Wang, Yixin Fang, Wei-Li He, Rui-Zhe Chen +1 more
2022Statistics in Biosciences4 citations
Semantic Scholar
Tirofiban combined with heparin’s effect and safety in the treatment of mild to moderate acute ischemic stroke
Tao Qiu, Changqing Li, Linming Huang, Hua Xiao +9 more
2020Neurological Research4 citations
Semantic Scholar
Sources of Data to Enable Benefit–Risk Assessment
C. Chuang-Stein, G. Quartey, Wei-Li He, Qi Jiang +4 more
20174 citations
Semantic Scholar
A Quantitative Approach for Benefit-Risk Assessment Using Stochastic Multi-Criteria Discriminatory Method
Yaping Wang, Yabing Mai, Wei-Li He
20164 citations
Semantic Scholar
Effective Drug Supply for Adaptive Clinical Trials: Recommendations by the DIA Adaptive Design Scientific Working Group Drug Supply Subteam
Nancy Burnham, Judith Quinlan, Wei-Li He, M. Marshall +4 more
2015Therapeutic Innovation and Regulatory Science4 citations
Semantic Scholar
A comparative study of the efficacy of tamoxifen and Chinese patented medicine (Pingxiao capsules) in gynecomastia: A retrospective cohort study
Q. Yao, He-ning Zhai, Hailang Huang, Junnan Lin +1 more
2022Andrologia3 citations
Semantic Scholar
Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management
Wei-Li He, Yixin Fang, Hongwei Wang, Ivan S. F. Chan
2021Statistics in Biopharmaceutical Research3 citations
Semantic Scholar
On a Stepwise Quantitative Approach for Benefit-Risk Assessment
Wei-Li He, Yaxuan Sun, Qing Li, Sabrina Wan
2017Therapeutic Innovation and Regulatory Science3 citations
Semantic Scholar
Overview of Benefit–Risk Evaluation Methods: A Spectrum from Qualitative to Quantitative
G. Quartey, Chun-Lei Ke, C. Chuang-Stein, Wei-Li He +4 more
20173 citations
Semantic Scholar
Practical considerations in utilizing cluster randomized controlled trials conducted in biopharmaceutical industry
Yixin Fang, Wei-Li He
2022Clinical Trials2 citations
Semantic Scholar
Visualization of Benefit–Risk Assessment in Medical Products with Real Examples
Shihua Wen, Wei-Li He, S. Evans, Haijun Ma +5 more
20172 citations
Semantic Scholar
Understanding and Evaluating Uncertainties in the Assessment of Benefit–Risk in Pharmaceutical Drug Development
Qi Jiang, Haijun Ma, C. Chuang-Stein, S. Evans +5 more
20172 citations
Semantic Scholar
Practical Considerations and Approaches for Emerging Issues in Benefit-risk Assessment of Medical Products
Wei-Li He, I. Chan, Qi Jiang
20162 citations Open access
Semantic Scholar
Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
Jun Liu, Wei-Li He, H. Quan
20072 citations
Semantic Scholar
Use of joint models to assess treatment effects on disease markers and clinical events: the ProscarTM Long-Term Efficacy and Safety Study (PLESS)
Wei-Li He, W. Shih
2004Clinical Trials2 citations
Semantic Scholar
A Flexible Ensemble Learning Method for Survival Extrapolation
Ran Dai, Jih-Yun Ma, Meijing Wu, Yabing Mai +1 more
2022Therapeutic Innovation and Regulatory Science1 citations
Semantic Scholar
Comment on “Good Data Science Practice: Moving towards a Code of Practice for Drug Development”
Yixin Fang, Wei-Li He
2022Statistics in Biopharmaceutical Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Qi Jiang×14
Invite
Qi Jiang — researcher profile on SciRah
Yixin Fang×10
Invite
Yixin Fang — researcher profile on SciRah
Hongwei Wang×9
Invite
Hongwei Wang — researcher profile on SciRah
C. Chuang-Stein×7
Invite
C. Chuang-Stein — researcher profile on SciRah

×6

Invite

John Scott — researcher profile on SciRah

Invite

G. Quartey — researcher profile on SciRah

Invite

S. Evans — researcher profile on SciRah

Invite

Haijun Ma — researcher profile on SciRah

Invite

Jie Chen — researcher profile on SciRah

Invite

Shihua Wen — researcher profile on SciRah

Invite

Y. Berd — researcher profile on SciRah

Invite

A. Mehta — researcher profile on SciRah